The incidence of diabetes mellitus has soared to epidemic proportion worldwide. The debilitating chronic hyperglycemia is caused by either lack of insulin as in diabetes type 1 or its ineffectiveness as in diabetes type 2. Frequent replacement of insulin with or without insulin analogs for optimum glycemic control are the conventional cumbersome therapies. Recent application of leptin gene transfer technology has uncovered the participation of adipocytes-derived leptin-dependent hypothalamic neural signaling in glucose homeostasis and demonstrated that a breakdown in this communication due to leptin insufficiency in the hypothalamus underlies the etiology of chronic hyperglycemia. Reinstatement of central leptin sufficiency by hyperleptinemia produced either by intravenous leptin infusion or a single systemic injection of recombinant adenovirus vector encoding leptin gene suppressed hyperglycemia and evoked euglycemia only transiently in rodent models of diabetes type 1. In contrast, stable restoration of leptin sufficiency, solely in the hypothalamus, with biologically active leptin transduced by an intracerebroventicular injection of recombinant adeno-associated virus vector encoding leptin gene (rAAV-lep) abolished hyperglycemia and imposed euglycemia through the extended duration of experiment by stimulating glucose disposal in the periphery in models of diabetes type 1. Further, similar hypothalamic leptin transgene expression abrogated chronic hyperglycemia and hyperinsulinemia, the predisposing risk factors of the age and environmentally acquired diabetes type 2, and instituted euglycemia by independently activating relays that stimulate glucose metabolism and repress hyperinsulinemia and improve insulin sensitivity in the periphery. Consequently, this durable antidiabetic efficacy of one time rAAV-lep neurotherapy offers a potential novel substitute for insulin therapy following preclinical trials in subhuman primates and humans.
INTRODUCTION
Diabetes mellitus is a chronic disease characterized by persistent hyperglycemia, which affects multiple systems and inflicts life-shortening peripheral and neural diseases attributable to an array of comorbidities such as obesity and dyslipidemia, hypertension, cardiovascular disease, nervous system damage underlying memory loss and Alzheimer's disease, retinopathy, peripheral neuropathy, infertility and kidney failure. [1] [2] [3] [4] [5] There are two main forms of diabetes mellitus. Diabetes type 1 is a debilitating childhood disease that manifests in response to progressive insulin deficiency resulting from a gradual loss of pancreatic b-cells inflicted by T-cell-mediated autoimmune disease. 2, 6, 7 Diabetes type 2 may be incurred at any age presumably in response to persistent metabolic derangements imposed by nutrient excess, lifestyle changes and aging. Dysregulation in internal metabolic milieu is generally thought to promote adiposity and deleterious patterns of adipokine secretions that, in turn, initiate the pathophysiologic metabolic sequelae of diabetes, that is, the initial rise in blood glucose and compensatory increase in pancreatic insulin secretion to normalize blood glucose, which if persistent, eventuates into hyperinsulinemia, insulin receptor insensitivity and post-receptor loss of signaling in liver, white adipose tissue and skeletal muscle, the peripheral participants in glucose disposal. 2, [7] [8] [9] [10] [11] The incidence of diabetes type 1 and 2 has increased dramatically over the past two decades with the latest projection of nearly doubling the global incidence of diabetes type 2 to 300 million people, including a significantly higher number of young adults by the year 2025-30. 11, 12 As the worldwide prevalence of obesity has also soared contemporaneously, it is widely believed that the antecedent peripheral deleterious effects of gradually accrued abnormal visceral fat and the accompanying high abundance of adipokines have orchestrated a parallel upswing in the incidence of diabetes in the general population to the current epidemic range. 8, 10, [13] [14] [15] [16] [17] [18] [19] However, clinical observations that neither all obese patients are diabetic nor all diabetics are obese, 2,3,9 that bariatric surgery of obese diabetic patients instantaneously resolves diabetes before any discernible evidence of weight loss, 20, 21 are not consistent with the contemporary view of this interactive cause and effect relationships solely in the periphery between these two metabolic diseases. This is corroborated by recent clinical and animal investigations that excess as well as complete absence of fat in the body are concomitant with hyperinsulinemia, insulin insensitivity and diabetes. 7, [22] [23] [24] [25] [26] [27] [28] The discovery of insulin in 1922 and the subsequent development of insulin analogs have been the life-saving treatments of hyperglycemia and in delaying or preventing the array of chronic complications of diabetes mellitus. 2, 13, [29] [30] [31] Diabetes, therefore, has traditionally been viewed as an affliction of either lack of or incomplete use of insulin and, consequently, conventional research has focused entirely on improving ways to deliver insulin for precision in attaining glycemic control to simulate the physiological range of blood glucose, necessary to combat the comorbidity cluster of this chronic malady. However, there is an emerging consensus that current therapies are cumbersome and are dependent upon intensive lifetime monitoring for tight glycemic control by patients and physicians at an ever soaring medical cost. 1, 5, 7, 8, 13, 14, 18, [30] [31] [32] Strategies to successfully halt the current worldwide epidemic of diabetes will require development of novel therapies based on the evolving new understanding of how lifestyle changes facilitated by technological advances, and coupled with consumption of energy-enriched diets, hasten derangements in glucose-insulin homeostasis and the mechanisms by which newly identified signal molecules participate in the life-long maintenance of glucose homeostasis. 2, 8, 10, 15, 23, 33, 34 In this context, recent attention has been devoted to the disclosure that dynamic physiological fluctuations in circulating titers of leptin, a hormone produced primarily by white adipose tissue under the direction of insulin, have a critical role in conferring glucose homeostasis indirectly through the central nervous system. 10, 16, [35] [36] [37] [38] [39] [40] [41] [42] The goals of this review are to collate major contributions emanating from research conducted with the aid of gene transfer technology in unraveling the neural etiology of this chronic disease of hyperglycemia, which is correctable by leptin gene therapy confined selectively to the hypothalamus, and that this neurotherapy can be gainfully employed to forestall the pathogenesis of diabetes and varied attendant comorbidities.
Leptin signaling to the hypothalamus in the etiology of diabetes: new insight The hypothalamus is the primary brain site of leptin action in integration of energy homeostasis. 10, 16, 23, 33, 34 Leptin, a 16 kD hormone, is transported across the blood brain barrier (BBB) by an active receptor-mediated process to diverse subpopulations of leptin receptor-expressing neurons in the hypothalamic nuclei ( Figure 1) . 10, 33, 41, [43] [44] [45] These neuronal subpopulations coexpress neuropeptides and amino-acid neurotransmitters that together constitute an appetite regulating network (ARN) and energy regulating network (EEN) in the basal hypothalamus. 10, 33, 34 These interconnected circuitries are normally engaged to regulate appetite and energy expenditure. 10, 33 How these two circuitries relay appropriate signals under the direction of circulating leptin for weight homeostasis has been reviewed extensively. 10, 16, 23, 33, 35, 42, 45, 46 More recently, a third leptin-responsive circuit in the hypothalamus, the fat accrual network (FAN) that operates independent of appetite regulating network and EEN to augment glucose metabolism and disposal in the periphery on the one hand, and restrain pancreatic insulin secretion, on the other hand, has been identified ( Figure 1 ). 10 Whether this hypothalamic circuit may have a significant role in the pathogenesis of diabetes is reinforced by the following evidence:
(1) Extensive retrograde-tracing studies show that neural projections of FAN do descend to liver, skeletal muscle, brown adipose tissue, white adipose tissue and pancreas to possibly relay regulatory information to these peripheral partners in maintaining glucose-insulin homeostasis ( Figure 1 ). 47-50 (2) Interruption of descending neural pathways to peripheral organs either surgically or by destruction of discrete hypothalamic nuclei resulted in loss of glucose homeostasis, as evidenced by persistence of hyperglycemia, hyperinsulinemia and diabetes, obesity and dyslipidemia. 10,33,51 (3) It is now abundantly clear that diabetes and the antecedent pathophysiologic sequelae-hyperinsulinemia and insulin insensitivity are contemporaneous with either complete leptin deficiency or leptinopenia in rodents and humans. 16, 22, 23, 26, 27, 52, 53 In leptin mutant (ob/ob) mice and congenitally leptin-deficient humans, the incessant hyperphagia and abnormal rate of weight gain are associated with hyperglycemia and hyperinsulinemia. 16, 23 Leptin replacement, either systemically or centrally without leakage to the periphery, reinstated euglycemia and normoinsulinemia before any discernible change in appetite or weight. 6, 23, [54] [55] [56] Severe leptinopenia in lean human subjects afflicted with congenital lipoatrophy or in experimentally produced lipodystrophic mice, also conferred hyperglycemia and insulin insensitivity, both readily resolved by leptin replacement therapy. 22, 27, 52 Similarly, lipoatrophy and leptin deficiency due to wasting inflicted by human immunodeficiency virus infection and treatment of human immunodeficiency virus-infected patients with antiretroviral treatment, are associated with insulin insensitivity and diabetes, both improved by daily leptin replacement. 25, 52, [57] [58] [59] Importantly, these antidiabetic effects of daily leptin replacement manifesting independent of any discernible impact on appetite and weight, involved hypothalamic leptin responsive pathways because mice with conditional leptin receptor knockout in the hypothalamus were diabetic 60 and instillation of leptin receptors selectively in the hypothalamus repressed hyperinsulinemia in the diabetic, leptin receptor mutant rats. 61 Thus, both leptin deficit and leptinopenia-induced insufficient hypothalamic leptin signaling are associated with dysregulation of the glucose-insulin axis. This inference seemingly appeared discordant with the epidemiological surveys showing increased risks of diabetes type 2 paralleling hyperleptinemia and obesity. 1, 8, 9, 14, 17, 18 However, a critical review 42 of leptin concentrations in cerebrospinal fluid consistently showed that hyperleptinemia either manifesting gradually in association with age-related obesity or that produced rapidly by consumption of energy-enriched diets, was associated with decreased brain leptin concentrations in rodents and humans (Figure 1 ). [62] [63] [64] [65] [66] [67] This diminution in brain leptin levels was attributable to restricted leptin entry across the BBB due to downregulation of leptin transport receptors on central nervous system vasculature caused by the unrelenting action of raging hyperleptinemia associated with increasing adiposity. 43, 44, 68 That this leptin insufficiency in the hypothalamus of obese subjects engenders hyperglycemia was endorsed by extinction of diabetes after reinstatement of leptin supply selectively in the hypothalamus of obese subjects. 5, 7, 69, 70 Thus, insufficiency in leptin signaling in the hypothalamus caused by either decreased availability of leptin for transport to hypothalamus in the case of leptinopenia, or restricted leptin entry across BBB imposed by hyperleptinemia in obese subjects, is primarily responsible for impelling hyperglycemia and hyperinsulinemia, the antecedent pathophysiologic sequelae, persistence of which culminate in diabetes mellitus. 7, 42 One is then confronted with the obvious questions of whether and how restoration of optimal leptin signaling in the hypothalamus would offer a new interventional therapeutic modality for this chronic disease.
Application of gene therapy to circumvent hypothalamic leptin insufficiency and ameliorate diabetes Overcoming leptin insufficiency on a long-term basis with endogenously produced leptin by transgene expression in the hypothalamus [69] [70] [71] [72] [73] [74] was found to be more efficient than exogenously delivered leptin via varied systemic routes (Figure 1) . 26, 36, 37, 53, 59, 75 These procedures were tedious, allowed only short-term delivery, required constant surveillance and were invariably associated with widespread distribution of leptin to targets within and outside the brain into the periphery where leptin was likely to increase the risks for multiple neural and peripheral ailments. 1, 9, 15, 42, 70, 76, 77 An injection of recombinant adenovirus-encoding leptin gene (Ad-lep) produced hyperleptinemia over several weeks suppressed weight gain, adiposity and blood insulin levels in normal adult rats. 78 These benefits were attributable to increased activation of hypothalamic leptin signaling because ablation of the basal hypothalamus abolished these hyperleptinemia-induced responses. 79 Similar transient benefits were reproduced by an injection of Ad-lep into the lateral cerebroventricles. 80 On the other hand, an intramuscular or intravenous injection of relatively non-immunogenic and non-pathogenic, replicationdeficient recombinant adeno-associated virus vector serotype 2 encoding leptin gene (rAAV-lep), raised blood leptin levels within the physiological range, normalized appetite and repressed obesity and blood insulin in obese, hyperinsulinemic ob/ob mice by appropriately modulating the hypothalamic appetite regulating network, EEN and FAN signaling for up to the 6-month duration of the experiment. 72, 73, 81 Similar efficacy lasting for the duration of experiment from several months to 2 years on weight homeostasis and insulin hypersecretion was reproduced in normal rats after an injection of rAAV-lep (serotype 2 and 5) into the third cerebroventicle or microinjection into discrete hypothalamic sites rich in biologically relevant leptin receptors (Figure1) . 73, 74, [82] [83] [84] [85] [86] [87] The effectiveness of central injections without leakage of transduced-leptin into either the cerebrospinal fluid or periphery, 86, 87 was evidenced by detection of increased leptin mRNA expression in the hypothalamus and visualization of the green fluorescent protein expression restricted in local hypothalamic sites. 5, 46, 70, 72, 73, 82, 83, 86, 87 Quite unexpectedly, these leptin transgene-expressing rodents consistently displayed euglycemia instead of the expected hyperglycemia in response to marked diminution in blood insulin levels. 2, 7, 54, 55, 83, [86] [87] [88] This divergent response of euglycemia contemporaneous with repressed blood insulin levels clearly identified a distinct regulatory role of hypothalamic leptin signaling in maintaining glucose homeostasis, either independent of insulin or concomitant with insulinopenia. 36, 37, 54, 88 This new insight into the obligatory and independent central roles of leptin, uncovered solely with the aid of central gene therapy technology, led to the formulation that circumvention of central leptin insufficiency with gene therapy may be a suitable therapeutic intervention to permanently impose glycemic stability. Verification of this hypothesis in various paradigms of diabetes type 1 and type 2 is summarized below.
Diabetes type 1
The effects of stable leptin delivery selectively to hypothalamic sites either by an intracerebroventicular (icv) rAAV injection into the third cerebroventicle or via transport of leptin across the BBB by systemic Ad-lep injection were evaluated in various rodent models of type 1 diabetic. Akita mice, a transgenic model of diabetes type 1 lacking biologically active insulin due to INS-2 gene mutation, are severely hyperglycemic and leptinopenic (Figure 1Ia) . 55, 56, 89, 90 Increased availability of leptin in the hypothalamus after an icv AAV-lep injection in these non-obese, adult diabetic mice conferred euglycemia within 1 week, a response sustained through the 7-weeks duration of the experiment . 56 The combined effects of the leptin therapy viz increased glucose metabolism and disposal by enhancing GLUT1 and GLUT4 in brown adipose tissue, liver and skeletal muscle asserted by increased leptin signaling along the FAN pathway, together with increased nonshivering thermogenic energy expenditure via EEN as evidenced by enhanced-brown adipose tissue UCP-1 mRNA, seemingly assisted in sustaining euglycemia in these mice. 38, 55, 56, 91, 92 Also, hyperleptinemia produced by systemic administration of Ad-lep in three type 1 diabetic rodents resulting from a loss of pancreatic b-cells either inflicted by autoimmune disease as in NOD (non-obese diabetic) mice, or chemically with streptozotocin or alloxan injections, corrected the severe hyperglycemia which was, however, transient paralleling the course of receding hyperleptenimia. 93 The efficacy of circulating leptin was also shown in these paradigms when intravenous infusion of leptin itself for 12 days rapidly impelled normoglycemia with a time course quite similar to that evoked by insulin replacement 94, 95 Furthermore, the possibility that restoration of optimal hypothalamic leptin signaling alone imposed euglycemia in these paradigms was verified when leptin supply was endogenously generated solely in the hypothalamus of hyperglycemic streptozotocin-treated mice. 96 An icv rAAV-lep injection 1 week after intravenous streptozotocin administration rapidly suppressed hyperglycemia to within the euglycemic range, and, thereafter, prevented weight loss and early mortality without any discernible behavioral abnormality or diabetic complication through 1 year of observation. 96 Collectively, these findings concur with the new insight that the primary cause of chronic hyperglycemia in diabetics type 1 is the development of leptin insufficiency in the hypothalamus as a consequence of diminished amount of leptin available for entry across the BBB, which can be ameliorated by restoration of optimal leptin supply with gene therapy selectively in the hypothalamus (Figure 1Ib ).
Diabetes type 2
Persistent hyperinsulinemia and the ensuing insulin resistance are currently viewed as the predisposing risk factors for diabetes type 2 in hyperleptinemic obese subjects. 2, [7] [8] [9] [10] [11] Evidence that hyperleptinemiainduced diminution in leptin levels in the hypothalamus curtails the restraint on pancreatic insulin secretion to allow hypersecretion needed to convert excess energy into fat depots, 7, 10, 42 and that central injections of leptin readily reinstate this restraint on pancreatic insulin efflux and improve insulin sensitivity (Figures 1IIa and b) , 7, 10 provided the impetus to evaluate whether restoration of leptin sufficiency with central leptin gene therapy may prevent these two predisposing risk factors of diabetes 2.
Indeed, an icv rAAV-lep injection readily suppressed the basal episodic insulin secretion for extended periods by attenuating the amplitude of secretory episodes from the pancreas in normal rats consuming low-fat rodent chow diet. 39, 40 A similar repression of pancreactic insulin efflux was reproduced in hyperinsulinemic rats and mice consuming energy-enriched diet. 40, 83, 97 The post-prandial insulin hypersecretion was also markedly dampened in these rats. 54 Moreover, this clamp on pancreatic insulin efflux was concomitant with markedly improved insulin sensitivity because extremely low insulin dosages that were ineffective in normal mice, significantly lowered blood glucose levels in these rodents. [54] [55] [56] 90 Suppression of basal insulin secretion by leptin transgene expression in the hypothalamus of both prepubertal or adult rats, persisted for the entire duration of the experiment lasting up to 2 years of observation, and through pregnancy and lactation in female rats. 87, 88, 98 This regulatory restraint was asserted solely through central pathways because icv rAAV-lep injection in leptin mutant hyperinsulinemic ob/ob mice, consuming either normal chow or energy-enriched diet, normalized blood insulin levels, improved insulin sensitivity along with suppressed adiposity and food intake for the lifetime despite the complete absence of leptin in blood. 54, 88 Further, central leptin gene therapy, in a manner quite similar to that observed in insulin-deficient type 1 diabetic rodents, 56, 90, 96 impelled euglycemia in both normoglycemic and hyperglycemic rodents along with suppressed blood insulin concentrations and improved insulin sensitivity (Figure 1IIb ).The novel insight that stable optimal leptin supply can sustain the restraint on insulin hypersecretion in concert with euglycemia for the lifetime of rodents, suggests that central leptin gene therapy has the potential to either delay or permanently block the environmentally acquired type 2 diabetes in the general population.
Leptin gene therapy and diabetes burden Several comorbidities of diabetes type 1 and 2 were also positively impacted by central leptin gene therapy. 5, 10 Leptin transgene expression normalized cardiovascular and systemic low grade inflammation disease markers, alleviated the symptoms of diabetic cardiomyopathy as reflected by oxidative stress parameters and apoptosis of heart muscles, and extinguished dyslipidemia. 14, 90, 99 Supply of a minute amount of leptin in the hypothalamus corrected various skeletal abnormalities and improved bone architecture, presumably by promoting secretion of osteoblast-specific osteocalcin, the hormone important in bone remodeling and retention of normal skeletal phenotype. 100, 101 Finally, a single central rAAV-lep injection reduced early mortality and doubled the lifespan of diabetic, obese ob/ob mice. 88 
Concluding remarks
Following the isolation, structural identity and elucidation of multiple physiological and pathophysiologic functions of leptin during these past decades, application of gene transfer technology to provide a stable supply of leptin, has uncovered an obligatory leptin-hypothalamic link in maintaining glucose homeostasis on a moment-tomoment basis, and disruption in this communication evidently enforces diabetic hyperglycemia. It is now clear that leptin secreted by adipocytes under the direction of insulin, is transported across the BBB to the hypothalamus by an active receptor-mediated process to regulate glucose homeostasis by a two-prong action. Activation of leptin-responsive central targets engenders two independently operating efferent signal relays along the FAN and EEN circuitries to peripheral organs to stimulate glucose disposal, and also to pancreatic b-cells to restrain basal and post-prandial insulin hypersecretion (Figure 1) . Genetic or environmentally acquired leptinopenia or hyperleptinemia provokes leptin insufficiency in the hypothalamus, which orchestrates diabetes. Central leptin repletion with the aid of either single systemic Ad-lep or central rAAV-lep injection in rodents suffering from diabetes type 1 readily confers long-lasting euglycemia by neurally asserting the optimal rate of glucose metabolism in the periphery. Similar restoration of optimal leptin signaling with the aid of central rAAV-lep therapy also ameliorates the environmentally acquired diabetes type 2 by additionally restraining insulin hypersecretion, and averts the life threatening comorbidities, including early mortality (Figure 1 ). How the neural and molecular mechanisms transduced by reinstated leptin signaling in the hypothalamus alone confer the life-long optimal rate of glucose metabolism and improved insulin sensitivity remains to be understood. Finally, in view of the current worldwide epidemic of diabetes, our demonstration of the safety and durability of a minute amount of bioactive leptin supply by central rAAV-lep injection, when considered together with the mounting evidence of the safety and benefits of ongoing clinical trials with rAAV vector for several neural diseases, [102] [103] [104] should serve as a strong catalyst for future exploration of the antidiabetic potential of the onetime rAAV-lep neurotherapy in subhuman primates and humans.
